The Food and Drug Administration approved Tregzi on June 30, 2026, marking the first regulatory T cell-based immunotherapy cleared for use in reducing chronic graft-versus-host disease among adults with blood cancers undergoing stem cell transplants.
The agency granted approval to Orca Biosystems, Inc. for the treatment, which targets a serious and often life-threatening complication that can develop after allogeneic hematopoietic stem cell transplantation, a procedure used to treat conditions such as acute leukemia and myelodysplastic syndrome.
What Tregzi Is and How It Works
Tregzi is composed of three distinct cell components drawn from a matched donor: purified hematopoietic stem and progenitor cells, regulatory T cells, known as Tregs, and conventional T cells. The donor must be an 8/8 HLA-matched relative or unrelated individual — a high level of genetic compatibility intended to reduce the risk of rejection or immune conflict.
The therapy is administered following chemotherapy used to condition the patient’s body ahead of a bone marrow or stem cell transplant. Chronic graft-versus-host disease occurs when donor immune cells attack the recipient’s tissues after a transplant, and it remains one of the leading causes of long-term illness and death following these procedures.
Karim Mikhail, Acting Director of the FDA’s Center for Biologics Evaluation and Research, described the significance of the clearance, saying the approval “offers a genuine new approach that can help reconstitute the immune system while substantially reducing that risk.”
Clinical Trial Results
The approval was based on results from the PRECISION-T clinical trial, which enrolled 187 adult patients diagnosed with blood cancers. Participants were randomly assigned to receive either Tregzi or a standard stem cell transplant, with the primary goal of measuring chronic GVHD-free survival within two years of the transplant date.
At the one-year mark, 78 percent of patients who received Tregzi had achieved chronic GVHD-free survival, compared to 38.4 percent of patients who received a standard transplant. The rate of serious chronic GVHD development told a similarly striking story: just 12.6 percent of Tregzi patients developed serious chronic GVHD within one year, versus 44 percent in the standard transplant group.
The most frequently reported side effect was infections. The trial recorded no cases of severe infusion reactions and no instances of graft failure during the study period.
Regulatory Designations and Agency Context
Tregzi received both Orphan Drug designation and Regenerative Medicine Advanced Therapy designation from the FDA, reflecting the agency’s recognition of its potential to address a serious unmet medical need in a small patient population.
The approval fits into a broader effort by federal health leadership to accelerate the path from research to patient access for innovative therapies. HHS Secretary Robert F. Kennedy Jr. has pushed the FDA to move faster on clinical trial processes, particularly as the United States competes with other nations in advanced medical research and development.
What Comes Next
With the approval now in place, Orca Biosystems will move toward making Tregzi commercially available to eligible adult patients at transplant centers equipped to handle complex cell therapy logistics. The treatment’s donor-matching requirements and multi-component structure mean it will be administered through specialized facilities rather than general oncology clinics.
Post-market data collection will likely be part of any ongoing regulatory commitments, as is standard for therapies granted advanced designations. Longer-term outcomes beyond the two-year trial window — including overall survival and quality-of-life measures — remain an area of continued interest as real-world data accumulates.
For patients and families navigating blood cancer diagnoses, the arrival of a new therapeutic option with this level of clinical differentiation from the existing standard of care represents a meaningful development. The FDA’s willingness to advance novel cell-based approaches through its expedited pathways signals continued agency focus on bringing breakthrough treatments to patients who have historically faced limited options.
Category: Health Policy & Agencies